Abstract Details

Title A Prospective Study: Clinical Significance of Anticholinergic Nasal Sprays in Patients with Parkinson Disease Afflicted by Rhinorrhea

Topic Movement Disorders

Presentation(s) P04 - (-)

Poster/Presentation
Number 149

Background BACKGROUND: Rhinorrhea is a common non motor symptom of parkinson's disease which hasn't been looked into until recently. The reported prevalence is quiet common between 24-50% in PD. This study looks at the therapeutic benefits of anticholinergic nasal sprays in PD patients with rhinorrhea.

Objective

Design/Methods DESIGN/METHODS: The data was derived through a series of patient interviews with questionnaires. Each patient was administered the sino-nasal outcome test-22 (SNOT-22) before and after 4 weeks of treatment with anticholinergic nasal spray- Atrovent® -ipratropium bromide.

Results RESULTS: All of our patients were equal or more than 60 years old and except for one patient all of them were males. The duration of diagnosis of PD was less than 7 years among this group of patients and they did not significant disability which would affect use of Nasal spray. Rhinorrhea was experienced within the first year of the PD for two of our patients. In this study, three patients had SNOT-22 score >20 and after using the nasal spray they experienced a clinical improvement of average 66%. The overall improvement was 58%. A higher dose was used in three of our patients and no side effects were reported by our patients.

Conclusions CONCLUSIONS: There was significant clinical improvement in rhinorrhea in PD patients with use of anticholinergic nasal spray- Atrovent® -ipratropium bromide. There were no major side effects noted with the use of the nasal spray.

Authors/Disclosures
Dennys Reyes, MD (Reyes Neurology) PRESENTER	No disclosure on file
Tarannum Khan, MD, MBBS, FAAN (Cleveland Clinic)	Dr. Khan has nothing to disclose.
Rachana Gandhi, MD (Wake Forest Baptist Medical Center)	Dr. Gandhi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Gandhi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Gandhi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam pharma. The institution of Dr. Gandhi has received research support from Akcea Therapeutics. The institution of Dr. Gandhi has received research support from UCB.
Val J. Lowe, MD (Mayo Clinic)	Dr. Lowe has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AVID Radiopharmaceutical. Dr. Lowe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai Inc. The institution of Dr. Lowe has received research support from AVID Radiopharmaceuticals.